Spero Therapeutics, Inc.
SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, includingā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.46
Price+2.93%
$0.07
1Y
Price
Market Cap
$138.437m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-20.0%
EBITDA Margin-14.4%
Net Profit Margin-149.9%
Free Cash Flow MarginRevenue
$40.501m
+47.8%
1y CAGR+25.1%
3y CAGR+60.4%
5y CAGREarnings
-$54.466m
+20.6%
1y CAGR-77.0%
3y CAGR-45.7%
5y CAGREPS
-$0.99
+22.1%
1y CAGR-79.4%
3y CAGR-45.1%
5y CAGRBook Value
$32.828m
$62.119m
Assets$29.291m
Liabilities$3.615m
DebtDebt to Assets
5.8%
-0.1x
Debt to EBITDAFree Cash Flow
-$32.333m
-37.9%
1y CAGR-111.9%
3y CAGR-61.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company